Showing results 1 to 20 of 23
next >
| Issue Date | Title | Author(s) |
| 5-Mar-2024 | Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia | Hu, Lijuan; Li, Zongru; Yang, Sen; Zhao, Ting; Duan, Wenbing; Qin, Yazhen; Jia, Jinsong; Wang, Jing; Lu, Shengye; Jiang, Hao; Zhang, Xiaohui; Xu, Lanping; Wang, Yu; Lai, Yueyun; Shi, Hongxia; Huang, Xiaojun; Jiang, Qian |
| 2015 | Behavior Analysis through Collaborative Visual Exploration on Trajectory Data | Ye, Tangzhi; Hao, Youfeng; Wang, Zhenhuang; Lai, Chufan; Chen, Siming; Li, Zongru; Liang, Jie; Yuan, Xiaoru |
| 2015 | Behavior analysis through collaborative visual exploration on trajectory data | Ye, Tangzhi; Hao, Youfeng; Wang, Zhenhuang; Lai, Chufan; Chen, Siming; Li, Zongru; Liang, Jie; Yuan, Xiaoru |
| 15-Nov-2022 | Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia | Zhang, Xiaoshuai; Li, Zongru; Qin, Ya-Zhen; Gale, Robert Peter; Lai, Yueyun; Shi, Hongxia; Huang, Xiao Jun; Jiang, Qian |
| 16-Mar-2021 | Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody | Sun, Xin; Peng, Min; Zhang, Ting; Li, Zongru; Song, Lan; Li, Mengtao; Shi, Juhong |
| 23-Nov-2021 | Correlations between Mutations in Cancer -Related Genes, Therapy Responses and Outcomes of the 3 (rd) Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy | Zhang, Xiaoshuai; Li, Zongru; Qin, Yazhen; Gale, Robert Peter; Huang, Xiaojun; Jiang, Qian |
| 15-Nov-2022 | A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China | Jiang, Qian; Li, Zongru; Qin, Ya-Zhen; Zhao, Ting; Liu, Bingcheng; Chen, Zi; Niu, Qian; Men, Lichuang; Wang, Hengbang; Yang, Dajun; Zhai, Yifan; Huang, Xiao-Jun |
| 2-Nov-2023 | Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor(TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy | Yu, Lu; Men, Lichuang; Li, Zongru; Huang, Xiaojun; Jiang, Qian |
| Jan-2022 | Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia | Zhu, Haichuan; Dong, Bingjie; Zhang, Yingchi; Wang, Mei; Rao, Jianan; Cui, Bowen; Liu, Yu; Jiang, Qian; Wang, Weitao; Yang, Lu; Yu, Anqi; Li, Zongru; Liu, Chao; Zhang, Leping; Huang, Xiaojun; Zhu, Xiaofan; Wu, Hong |
| 2017 | Interaction plus : Interaction Enhancement for Web-based Visualizations | Lu, Min; Liang, Jie; Zhang, Yu; Li, Guozheng; Chen, Siming; Li, Zongru; Yuan, Xiaoru |
| 2017 | Interaction+: Interaction enhancement for web-based visualizations | Lu, Min; Liang, Jie; Zhang, Yu; Li, Guozheng; Chen, Siming; Li, Zongru; Yuan, Xiaoru |
| May-2022 | Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia | Li, Zongru; Peng, Li; Li, Yongjie; Zhang, Jun; Jiang, Qian |
| 8-Jun-2021 | Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services | Bao, Mei; Yang, Sen; Gale, Robert Peter; Zhang, Yanli; Liu, Xiaoli; Zhu, Huanling; Liang, Rong; Liu, Bingcheng; Zhou, Li; Li, Zongru; Dou, Xuelin; Shi, Dayu; Wang, Tao; Meng, Li; Li, Weiming; Jiang, Qian |
| Jun-2020 | Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation | Li, Zongru; Lai, Yueyun; Zhang, Xiaohui; Xu, Lanping; Liu, Kaiyan; Wang, Yu; Yan, Chenhua; Jiang, Hao; Huang, Xiaojun; Jiang, Qian |
| 2-Nov-2023 | Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Faile | Li, Zongru; Ting, Zhao; Hu, Lijuan; Duan, Wenbing; Jiang, Qian |
| 18-Aug-2022 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 31-Oct-2022 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 20-Feb-2023 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| Apr-2024 | STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2+T cells in acute myeloid leukemia | Cheng, Cong; Liang, Shuang; Yue, Keli; Wu, Ning; Li, Zongru; Dong, Tianhui; Dong, Xinyu; Ling, Min; Jiang, Qian; Liu, Jiangying; Huang, Xiao-Jun |
| 23-Nov-2021 | Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) | Qian, Jiang; Shi, Dayu; Li, Zongru; Hou, Yue; Hu, Yu; Li, Weiming; Liu, Xiaoli; Xu, Na; Song, Yongping; Zhang, Gongli; Meng, Li; Hong, Zhenya; Liu, Bingcheng; Li, Yan; Chen, Suning; Xue, Mengxing; Zhu, Huanling; Li, He; Du, Xin; Lou, Jin; Zhang, Xiaohan; Liang, Yang; Dai, Yujun; Chen, Zi; Niu, Qian; Men, Lichuang; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
